Showing results (81-90 of 96) with videos related to

Sort By:
Pageof 10
Frontiers in Allergy|April 4, 2025
Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a post hoc analysis from the ANANKE studyLuisa Brussino, Maria Aliani, Elena Altieri, et al.
Frontiers in Immunology|April 17, 2023
Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polypsCorrado Pelaia, Alida Benfante, Maria Teresa Busceti, et al.
Journal of Asthma and Allergy|April 2, 2024
Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE StudyPaolo Cameli, Maria Aliani, Elena Altieri, et al.
The World Allergy Organization Journal|January 26, 2026
Clinical remission in patients with severe eosinophilic asthma treated with benralizumab over 24 months: Post hoc analysis of the ANANKE studyGiorgio Walter Canonica, Gianenrico Senna, Luisa Brussino, et al.
Respiratory Research|May 20, 2023
Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE studyAlessandra Vultaggio, Maria Aliani, Elena Altieri, et al.
ERJ Open Research|February 18, 2026
Former smokers with severe eosinophilic asthma respond to benralizumab as effectively as never-smokers: a post hoc analysis of the ANANKE studyGianenrico Senna, Luisa Brussino, Maria Aliani, et al.
Frontiers in Medicine|September 19, 2022
Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysisCristiano Caruso, Paolo Cameli, Elena Altieri, et al.
Frontiers in Allergy|June 30, 2022
Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc AnalysisMaria D'Amato, Francesco Menzella, Elena Altieri, et al.
Respiratory Research|February 20, 2022
ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE studyFrancesco Menzella, Elena Bargagli, Maria Aliani, et al.
Journal of Asthma and Allergy|November 17, 2022
Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE StudyGianenrico Senna, Maria Aliani, Elena Altieri, et al.
Pageof 10